Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meredith Sagal

Nurse Practitioner, Family Hunt Valley, MD Nurse Practitioner

NPI 1932644457 CMS profile 10687768

10153 York Rd Ste 104, Hunt Valley, MD 21030

Open in the dashboard

General payments

$81,832

936 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Sagal of Hunt Valley, MD is reported in the CMS Open Payments database as having received $81,832 across 936 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,343 259
2024 General $36,016 255
2023 General $11,994 180
2022 General $3,817 134
2021 General $2,662 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Sagal
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Meredith Sagal were reported at $27,343. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Meredith Sagal Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,662 $124 $35–$379 $132
2022 $3,817 $141 $44–$430 $149
2023 $11,994 $154 $49–$476 $160
2024 $36,016 $165 $51–$504 $164
2025 $27,343 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $39,583 148 payments
  2. E.R. Squibb & Sons, L.L.C. $14,725 79 payments
  3. Galderma Laboratories, L.P. $10,120 69 payments
  4. AbbVie, Inc. $3,283 99 payments
  5. Lilly USA, LLC $1,541 30 payments
  6. Regeneron Healthcare Solutions, Inc. $1,335 45 payments
  7. Dermavant Sciences, Inc. $1,260 64 payments
  8. Novartis Pharmaceuticals Corporation $1,258 67 payments
  9. UCB, Inc. $1,230 36 payments
  10. LEO Pharma Inc. $1,103 46 payments
  11. Other $6,394 253 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,161 30 payments
  2. Food and Beverage $23,829 860 payments
  3. Travel and Lodging $5,248 26 payments
  4. Consulting Fee $4,296 4 payments
  5. Education $992 14 payments
  6. Honoraria $305 2 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $39,566 147 payments
  2. SOTYKTU $12,704 75 payments
  3. NEMLUVIO $5,642 26 payments
  4. RINVOQ $1,575 42 payments
  5. VTAMA $1,416 71 payments
  6. SKYRIZI $1,274 39 payments
  7. DUPIXENT Immunology $1,165 43 payments
  8. OPZELURA $881 29 payments
  9. DUPIXENT Inflammation And Immunology $875 29 payments
  10. ADBRY $858 40 payments
  11. Other $11,856 486 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

603

Median for Nurse Practitioner: 389

Drug cost

$75,953

Median for Nurse Practitioner: $21,885

Branded share of claims

6.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 13 $48,067
Jublia Efinaconazole Brand 12 $10,730
Clobetasol Propionate Generic 44 $4,128
Fluorouracil Generic 37 $2,092
Ketoconazole Generic 79 $1,826
Tacrolimus Generic 11 $1,608
Clindamycin Phosphate Generic 37 $1,091
Metronidazole Generic 25 $1,043
Fluocinonide Generic 36 $982
Betamethasone Dipropionate Generic 20 $803

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$121,335

Of which drugs: $1,291

Medicare patients

721

Average age 73

Services billed

3,520

500 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 44%
Osteoporosis 22%
Ischemic heart disease 19%
Diabetes 18%
Depression 17%
Cancer 14%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 27 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$18,834 — —
SOTYKTU
$8,062 — —
VTAMA
$705 — —
RINVOQ
$500 — —
OLUMIANT
$325 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

936 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record